GURUFOCUS.COM » STOCK LIST » Latin America » Argentina » BUE » Biogen Inc (BUE:BIIB) » Definitions » EPS (Basic)
Switch to:

Biogen (BUE:BIIB) EPS (Basic)

: ARS3,136.37 (TTM As of Mar. 2023)
View and export this data going back to 2019. Start your Free Trial

Biogen's basic earnings per share (Basic EPS) for the three months ended in Mar. 2023 was ARS531.41. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2023 was ARS3,136.37.

Biogen's EPS (Diluted) for the three months ended in Mar. 2023 was ARS527.46. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was ARS3,123.41.

Biogen's EPS without NRI for the three months ended in Mar. 2023 was ARS527.46. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2023 was 3,123.41.

During the past 12 months, Biogen's average EPS without NRIGrowth Rate was 120.50% per year. During the past 3 years, the average EPS without NRI Growth Rate was -12.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 1.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was 10.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Biogen's highest 3-Year average EPS without NRI Growth Rate was 205.20% per year. The lowest was -66.00% per year. And the median was 26.65% per year.


Biogen EPS (Basic) Historical Data

The historical data trend for Biogen's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EPS (Basic)
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 815.56 1,881.08 2,023.11 1,054.34 3,513.94

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
EPS (Basic) Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 221.19 872.39 1,092.15 640.42 531.41

Biogen EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Biogen's Basic EPS for the fiscal year that ended in Dec. 2022 is calculated as

Basic EPS (A: Dec. 2022 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(510812.771-0)/145.300
=3,515.57

Biogen's Basic EPS for the quarter that ended in Mar. 2023 is calculated as

Basic EPS (Q: Mar. 2023 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(76629.647-0)/144.400
=530.68

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS3,136.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen  (BUE:BIIB) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Biogen EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Biogen's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (BUE:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BUE:BIIB) Headlines